In FOURIER, event adjudication followed a rigorous, pre-specified, blinded process by the TIMI CEC using all relevant & available source docs. A recent attempt at reanalysis is fundamentally flawed, using incomplete data to reach incorrect conclusions. Full rebuttal forthcoming!

Rigorous #FOURIER event adjudication explained - misguided & uninformed attacks refuted! timi.org/bmjopenrespons…

🟡 ANGPTL3 Inhibition, Dyslipidemia, and Cardiovascular Diseases #CardioEd #Cardiology #CardioTwitter

Can cardiac biomarkers help identify T2D patients at higher risk of atherosclerotic events and who benefit more from dapagliflozin? Find out in our paper ja.ma/3II1c6v via JAMA Cardiology part of JAMA Network Stephen Wiviott TIMI Study Group Kardiologie MedUni Wien Forschung MedUni Wien

@ZelnikerThomas TIMI Study Group

Are you analysing GFR slope in a study? See our new SMART-C GitHub page (by Robert Fletcher) with reproducible R code, synthetic data & explanation on how to calculate acute, chronic & total slope like in the CREDENCE and DAPA-CKD trials More coming soon: github.com/SGLT2-Trialist…

Sotagliflozin (INPEFA) receives *broad* U.S. FDA approval based on #SOLOISTWHF & #SCORED to reduce CV death, HF hosp, & urgent HF visits in either: HF or T2D, CKD, and CV risk factors A 3rd #SGLTi for the indication of HF treatment irrespective of LVEF lexpharma.com/media-center/n…

Wow, wow, wow! In SELECT trial of patients with obesity (mean BMI 33, n>17,000) & prior atherosclerotic cardiovascular disease (but no diabetes), GLP-1 agonist semaglutide 2.4mg once-weekly reduced risk of CV death, heart attack, or stroke (RRR 20%) novonordisk.com/content/nncorp…

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity | NEJM nejm.org/doi/full/10.10… #ESC2023 Prof Kamlesh Khunti Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Mikhail Kosiborod European Society of Cardiology Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦

Topline results from AZALEA-TIMI 71 featured in Medscape medscape.com/viewarticle/99…

Welcome, #PCHF Alumni '26🌎🌍🌏The Postgraduate Course in #HeartFailure continues to empower #global cardiovascular health with a proficient network of > 320 international alumni ready to tackle #HeartFailure 🫀heartfailure.com University of Zurich Unispital_USZ Radiologie USZ

The FLOW trial results are live at @nejm as well #ERA24 nejm.org/doi/full/10.10… Primary composite kidney ✅ CV Death✅ All cause death ✅ GFR slope ✅ First MACE ✅ Kidney specific composite ✅

GLP-1RAs completing the FAB 4 for DM2 and CKD 😃🎉 FLOW trial + metaanalysis results ERA - European Renal Association today whats the effect on top of FAB 3? (16% on SGLT2i, ?% on MRA)

SMART-C: 12 trials, 3000 on GLP1 - effects of SGLT2 consistent irrespective of GLP1 AMPLITUDE+HARMONY: 1200 on SGLT2 - effects of GLP1 consistent regardless of SGLT2 FLOW detailed SGLT2i data anticipated All suggests independent effects and supports combo Rx #ERA24 ERA - European Renal Association

eGFR slope analyses from SMART-C Brendon Neuen - my favourite figure from this meta-analysis presented on the day FLOW caused waves at #ERA2024 - it looks like GLP1-RA must be upgraded to standard of care for albuminuric DKD with the other pillars 😃

Wow, another win for patients with #HFpEF and obesity! This time with dual incretin tirzepatide in #P3 #SUMMIT trial Co-primary endpoint of worsening HF events reduced by 38% HR 0.62 95% CI 0.41 to 0.95; P=0.026 investor.lilly.com/news-releases/…

More good news for pts living with HF with EF >|= 40%!! Positive top line results of FINEARTS trial with non-steroidal MRA Finerenone Looking forward to seeing full data at ESC!! European Society of Cardiology bayer.com/media/en-us/fi…

Today’s talks at MedUni Wien were truly next-level! Matthias Tschöp on obesity breakthroughs, followed by cardiovascular rounds with Eugene Braunwald discussing 'Hypertrophic Cardiomyopathy - Past, Present, Future.' Kardiologie MedUni Wien Forschung TIMI Study Group Mass General Brigham

A moment to remember! Dr. Eugene Braunwald from TIMI Study Group leading virtual cardiovascular rounds at MedUni Wien Kardiologie MedUni Wien Forschung